Charles River Laboratories International, Inc.’s Stock Price Drops to $196.96, Experiencing a 3.12% Decrease: Time to Buy?

Charles River Laboratories International, Inc. (CRL)

196.96 USD -6.34 (-3.12%) Volume: 0.61M

Charles River Laboratories International, Inc.’s stock price is currently at 196.96 USD, experiencing a slight dip of -3.12% in this trading session. Despite a trading volume of 0.61M, the stock has seen a year-to-date percentage decrease of -16.68%, indicating a bearish trend in CRL’s market performance.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories International (CRL) experienced a decline in its stock price today, attributed to a more cautious funding environment. Despite this, recent news indicates that Amica Mutual Insurance Co. has purchased shares of the company, reflecting some investor confidence in its potential. The investigation announced for long-term investors in Charles River Laboratories shares raises questions about the company’s future performance. Wall Street’s sentiment towards the stock remains uncertain, with both bullish and bearish perspectives circulating in the market.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to the Smartkarma Smart Scores, Charles River Laboratories has a mixed long-term outlook based on its overall scores. While the company scores well in terms of value, growth, and momentum, it lags behind in terms of dividend and resilience. This indicates that while Charles River Laboratories may offer good value and potential for growth, investors may need to consider the company’s dividend payout and ability to weather economic downturns.

Charles River Laboratories International, Inc. is a company that provides research tools and support services for drug discovery and development. They specialize in offering animal research models necessary for the development of new drugs, devices, and therapies. With a customer base that includes pharmaceutical and biotechnology companies, hospitals, and academic institutions, Charles River Laboratories plays a crucial role in advancing medical research and innovation.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma